Cue Biopharma Q4 revenue surges on ImmunoScape deal

Cue Biopharma

16/03/2026 20:28

Overview

U.S. biopharma firm's Q4 collaboration revenue surged on ImmunoScape deal

Company posted Q4 net income, reversing a loss from the prior year

R&D expenses rose due to CUE-401 development and ImmunoScape collaboration costs

Outlook

Company did not provide specific financial guidance or outlook for the current or future periods

Result Drivers

IMMUNOSCAPE COLLABORATION - Q4 revenue increase was primarily due to upfront payments from ImmunoScape collaboration and license agreement

CUE-401 DEVELOPMENT COSTS - R&D expenses rose due to increased drug substance manufacturing and lab costs for CUE-401, and one-time acquired in-process R&D costs tied to ImmunoScape collaboration

LOWER COMPENSATION EXPENSE - Decrease in employee compensation, including stock-based compensation, due to reduction in headcount partially offset expense increases

Company press release: ID:nGNX4HQ8ZW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$21.94 mln
Q4 Net Income
$1.59 mln
Q4 Basic EPS
$0.01
Q4 Income From Operations
$1.98 mln
Q4 Operating Expenses
$19.96 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cue Biopharma Inc is $4.00, about 1,309.9% above its March 13 closing price of $0.28

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)